Clinical exome sequencing in neurogenetic and neuropsychiatric disorders

Exome sequencing has recently been elevated to the standard of care for genetic diagnostic testing, particularly for genetically diverse and clinically heterogeneous disorders. This review provides a clinically oriented discussion of the next‐generation sequencing technology that makes exome sequencing possible and how such technology is applied to the diagnosis of Mendelian disease, including clinically significant de novo variation, interpretation of variants of uncertain clinical significance, the future potential for genetic assessments of disease risk, and the substantial benefits in diagnostic efficiency. Important caveats are also discussed, including the implications of incidental or secondary findings detected during exome sequencing and the relationship of exome sequencing to other methods of clinical genomic testing, such as chromosomal microarray and genome sequencing. Overall, the widespread adoption and use of exome sequencing in routine clinical practice is expected to improve diagnosis rates and reduce test costs, while leading to improvements in patient outcomes and a renewed emphasis on disease management.

[1]  W. Chung,et al.  Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics , 2016, Genetics in Medicine.

[2]  S. Bale,et al.  Assessing copy number from exome sequencing and exome array CGH based on CNV spectrum in a large clinical cohort , 2014, Genetics in Medicine.

[3]  Xiang Li,et al.  Enhanced utility of family-centered diagnostic exome sequencing with inheritance model–based analysis: results from 500 unselected families with undiagnosed genetic conditions , 2014, Genetics in Medicine.

[4]  Yuan Xue,et al.  Solving the molecular diagnostic testing conundrum for Mendelian disorders in the era of next-generation sequencing: single-gene, gene panel, or exome/genome sequencing , 2014, Genetics in Medicine.

[5]  Lars T Westlye,et al.  Polygenic risk for schizophrenia associated with working memory-related prefrontal brain activation in patients with schizophrenia and healthy controls. , 2015, Schizophrenia bulletin.

[6]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[7]  Joshua L. Deignan,et al.  De novo nonsense mutations in KAT6A, a lysine acetyl-transferase gene, cause a syndrome including microcephaly and global developmental delay. , 2015, American journal of human genetics.

[8]  Y Wang,et al.  Genetic pleiotropy between multiple sclerosis and schizophrenia but not bipolar disorder: differential involvement of immune-related gene loci , 2014, Molecular Psychiatry.

[9]  P. Sullivan,et al.  No evidence for rare recessive and compound heterozygous disruptive variants in schizophrenia , 2014, European Journal of Human Genetics.

[10]  A. StAteMent ACMG policy statement: updated recommendations regarding analysis and reporting of secondary findings in clinical genome-scale sequencing , 2014, Genetics in Medicine.

[11]  T. Wassink,et al.  A genome‐wide CNV analysis of schizophrenia reveals a potential role for a multiple‐hit model , 2014, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[12]  N. Matsumoto,et al.  Genetics: Clinical exome sequencing in neurology practice , 2014, Nature Reviews Neurology.

[13]  D. Rujescu,et al.  Exome Sequencing in 53 Sporadic Cases of Schizophrenia Identifies 18 Putative Candidate Genes , 2014, PloS one.

[14]  Magalie S Leduc,et al.  Molecular findings among patients referred for clinical whole-exome sequencing. , 2014, JAMA.

[15]  Eric Vilain,et al.  Clinical exome sequencing for genetic identification of rare Mendelian disorders. , 2014, JAMA.

[16]  D. G. Clark,et al.  Effects of multiple genetic loci on age at onset in late-onset Alzheimer disease: a genome-wide association study. , 2014, JAMA neurology.

[17]  Siddharth Srivastava,et al.  Clinical whole exome sequencing in child neurology practice , 2014, Annals of neurology.

[18]  Soma Das,et al.  Clinical exome sequencing: the new standard in genetic diagnosis. , 2014, JAMA neurology.

[19]  Joshua L. Deignan,et al.  Exome sequencing in the clinical diagnosis of sporadic or familial cerebellar ataxia. , 2014, JAMA neurology.

[20]  Sebastien Ourselin,et al.  Functional connectivity in autosomal dominant and late-onset Alzheimer disease. , 2014, JAMA neurology.

[21]  M. Nalls,et al.  Genome-wide analysis of the heritability of amyotrophic lateral sclerosis. , 2014, JAMA neurology.

[22]  James T Lu,et al.  Genotype-phenotype correlation--promiscuity in the era of next-generation sequencing. , 2014, The New England journal of medicine.

[23]  L. Vissers,et al.  Parental somatic mosaicism is underrecognized and influences recurrence risk of genomic disorders. , 2014, American journal of human genetics.

[24]  Julia Wynn,et al.  The usefulness of whole-exome sequencing in routine clinical practice , 2014, Genetics in Medicine.

[25]  A. Singleton,et al.  Next generation sequencing techniques in neurological diseases: redefining clinical and molecular associations , 2014, Human molecular genetics.

[26]  G. Comi,et al.  A genome-wide association meta-analysis identifies a novel locus at 17q11.2 associated with sporadic amyotrophic lateral sclerosis. , 2014, Human molecular genetics.

[27]  J. Shendure,et al.  A de novo convergence of autism genetics and molecular neuroscience , 2014, Trends in Neurosciences.

[28]  Allyn McConkie-Rosell,et al.  The utility of the traditional medical genetics diagnostic evaluation in the context of next-generation sequencing for undiagnosed genetic disorders , 2013, Genetics in Medicine.

[29]  J. Veltman,et al.  Clinical exome sequencing in daily practice: 1,000 patients and beyond , 2014, Genome Medicine.

[30]  Eric Vilain,et al.  Assessing the necessity of confirmatory testing for exome sequencing results in a clinical molecular diagnostic laboratory , 2014, Genetics in Medicine.

[31]  Mustafa Tekin,et al.  The promise of whole-exome sequencing in medical genetics , 2013, Journal of Human Genetics.

[32]  Magalie S Leduc,et al.  Clinical whole-exome sequencing for the diagnosis of mendelian disorders. , 2013, The New England journal of medicine.

[33]  Qingguo Wang,et al.  Computational tools for copy number variation (CNV) detection using next-generation sequencing data: features and perspectives , 2013, BMC Bioinformatics.

[34]  Utilization of genetic testing prior to subspecialist referral for cerebellar ataxia. , 2013, Genetic testing and molecular biomarkers.

[35]  Marc S. Williams,et al.  ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing , 2013, Genetics in Medicine.

[36]  Tommaso Mazza,et al.  Congruency in the prediction of pathogenic missense mutations: state-of-the-art web-based tools , 2013, Briefings Bioinform..

[37]  Sudhir Kumar,et al.  Performance of computational tools in evaluating the functional impact of laboratory-induced amino acid mutations , 2012, Bioinform..

[38]  J. Shendure,et al.  Exome sequencing as a tool for Mendelian disease gene discovery , 2011, Nature Reviews Genetics.

[39]  Hugo Y. K. Lam,et al.  Performance comparison of exome DNA sequencing technologies , 2011, Nature Biotechnology.

[40]  Brent L Fogel Interpretation of genetic testing: variants of unknown significance. , 2011, Continuum.

[41]  M. Vihinen,et al.  Performance of mutation pathogenicity prediction methods on missense variants , 2011, Human mutation.

[42]  Kenny Q. Ye,et al.  Mapping copy number variation by population scale genome sequencing , 2010, Nature.

[43]  A. Al-Chalabi,et al.  An estimate of amyotrophic lateral sclerosis heritability using twin data , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[44]  S. Ferdinandusse,et al.  Identification of an unusual variant peroxisome biogenesis disorder caused by mutations in the PEX16 gene , 2010, Journal of Medical Genetics.

[45]  Leslie G Biesecker,et al.  Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. , 2010, American journal of human genetics.

[46]  S. Nelson,et al.  Improving the efficiency of genomic loci capture using oligonucleotide arrays for high throughput resequencing , 2009, BMC Genomics.

[47]  Kai Ye,et al.  Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads , 2009, Bioinform..

[48]  David T. Okou,et al.  Microarray-based genomic selection for high-throughput resequencing , 2007, Nature Methods.

[49]  Philip M. Kim,et al.  Paired-End Mapping Reveals Extensive Structural Variation in the Human Genome , 2007, Science.

[50]  G. Weinstock,et al.  Direct selection of human genomic loci by microarray hybridization , 2007, Nature Methods.

[51]  Hanlee P. Ji,et al.  Multigene amplification and massively parallel sequencing for cancer mutation discovery , 2007, Proceedings of the National Academy of Sciences.

[52]  Hanlee P. Ji,et al.  Multiplex amplification of all coding sequences within 10 cancer genes by Gene-Collector , 2007, Nucleic acids research.

[53]  James R. Knight,et al.  Genome sequencing in microfabricated high-density picolitre reactors , 2005, Nature.

[54]  J. Shendure,et al.  Materials and Methods Som Text Figs. S1 and S2 Tables S1 to S4 References Accurate Multiplex Polony Sequencing of an Evolved Bacterial Genome , 2022 .

[55]  Fredrik Dahl,et al.  Multiplex amplification enabled by selective circularization of large sets of genomic DNA fragments , 2005, Nucleic acids research.

[56]  F. Collins,et al.  The Human Genome Project: Lessons from Large-Scale Biology , 2003, Science.

[57]  International Human Genome Sequencing Consortium Initial sequencing and analysis of the human genome , 2001, Nature.

[58]  Arnold Munnich,et al.  Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia , 1994, Nature.

[59]  D. Church,et al.  Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia , 1994, Cell.

[60]  F. Sanger,et al.  DNA sequencing with chain-terminating inhibitors. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[61]  T. Bird,et al.  Clinical neurogenetics , 1977, Neurology.